Skip to main content
. Author manuscript; available in PMC: 2015 May 13.
Published in final edited form as: Cancer Res. 2008 Oct 1;68(19):7811–7818. doi: 10.1158/0008-5472.CAN-08-1320

Table 2.

Number of metastatic foci

shControl
(per animal)		 shAGR2-1
(per animal)		 Percentage of
reduction		 shControl + Gem
(per animal)		 shAGR2-1 + Gem
(per animal)		 Percentage of
reduction
Lung 3.8 ± 0.7 1.8 ± 0.5* 47% 0.6 ± 0.18 0* 100%
Liver 10.2 ± 0.9 6.5 ± 1.2* 64% 2.0 ± 1.0 0.4 ± 0.2* 80%

NOTE: AGR2 silencing combined with gemcitabine treatment reduces the number of metastatic foci in vivo. Tumors were developed in nude mice with MPanc-96 cells stably expressing shAGR2-1 or shControl and also expressing the luciferase gene, and these animals were treated with and without gemcitabine. At the end of the experiment, cancer cells were quantitated by bioluminescence imaging and numbers of metastatic foci were counted in lung and liver. AGR2 silencing significantly reduced the lung and liver metastatic foci, whereas combination with gemcitabine further reduced them. Data shown are mean ± SE for five animals.

Abbreviation: Gem, gemcitabine.

*

P < 0.05 versus control.

HHS Vulnerability Disclosure